e-learning
resources
Munich 2014
Sunday, 07.09.2014
Novel evidence relating to respiratory treatment development
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Comparison of budesonide and fluticasone propionate on COPD macrophage phagocytosis and killing of bacteria
K. Belchamber, A. Turner, R. Holloway, P. Barnes, L. Donnelly (London, United Kingdom)
Source:
International Congress 2014 – Novel evidence relating to respiratory treatment development
Session:
Novel evidence relating to respiratory treatment development
Session type:
Thematic Poster Session
Number:
957
Disease area:
Airway diseases, Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. Belchamber, A. Turner, R. Holloway, P. Barnes, L. Donnelly (London, United Kingdom). Comparison of budesonide and fluticasone propionate on COPD macrophage phagocytosis and killing of bacteria. Eur Respir J 2014; 44: Suppl. 58, 957
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Related content which might interest you:
Pharmacological activities of roflumilast N-oxide, dexamethasone and formoterol in human neutrophils from healthy non-smokers and COPD patients
Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases
Year: 2014
Comparison of fluticasone, roflumilast and tiotropium in a model of influenza-induced acute COPD exacerbation
Source: Annual Congress 2013 –New drugs in respiratory medicine
Year: 2013
Effects of combining tiotropium and salmeterol/fluticasone propionate on airway dimensions in patients with COPD
Source: Annual Congress 2013 –Novel mechanisms for established drugs for asthma and COPD management
Year: 2013
Differential effects of budesonide and fluticasone propionate on bacterial recognition receptors in COPD macrophages
Source: International Congress 2016 – Airway response to infection
Year: 2016
Comparison of fluticasone propionate and budesonide on phagocytosis of common respiratory pathogens in COPD patients
Source: Annual Congress 2011 - Immunology and cell biology of asthma and COPD
Year: 2011
Effects of ciclesonide on the management of stable COPD with airway eosinophilia
Source: Annual Congress 2013 –COPD treatment and others
Year: 2013
Exacerbator subtypes in the tiotropium safety and performance in respimat (TIOSPIR™) trial
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
The impact of stepwise withdrawal of inhaled corticosteroids on exacerbations in COPD patients receiving dual bronchodilation: WISDOM study
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014
Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice
Source: Eur Respir J 2002; 20: 819-825
Year: 2002
Effect of aclidinium bromide on exacerbations in patients with moderate-to-severe COPD: Pooled analysis of phase III studies
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014
The adherence to inhaled drugs in COPD patients: Effect on survival
Source: International Congress 2015 – Treatment and control of respiratory disease
Year: 2015
The impact of stepwise withdrawal of inhaled corticosteroids on lung function in COPD patients receiving dual bronchodilation: WISDOM study
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Improved effects of aerosol-type fluticasone propionate/formoterol combination on residual asthmatic inflammation in distal airways of patients with moderate asthma
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
The combination therapy with inhaled tiotropium bromide and indacaterol in COPD improves the peripheral airway function in static and dynamic status
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Erdosteine oral treatment of hospitalised COPD exacerbation prolongs time to first re-exacerbation
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014
Comparison of indacaterol with tiotropium or once-daily dual long-acting bronchodilator therapy with roflumilast for severe COPD
Source: International Congress 2014 – Markers
Year: 2014
Impact of mucolytic treatment on COPD exacerbations
Source: Annual Congress 2013 –Cell biology and murine models of asthma and inflammation
Year: 2013
Effect of inhaled vilanterol trifenatate/fluticasone furoate on breathing pattern, dyspnea and respiratory muscle function in severe COPD
Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases
Year: 2014
Evaluation of airway sGaw in Japanese COPD patients treated with triple therapy using salmeterol/fluticasone propionate 50/250 and tiotropium bromide
Source: International Congress 2015 – COPD: interesting notes
Year: 2015
Blood eosinophil guided prednisolone therapy for exacerbations of COPD: A further analysis
Source: International Congress 2014 – COPD exacerbations
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept